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OBJECTIVES We sought to assess the effect of baseline ejection fraction on survival difference between
patients with life-threatening ventricular arrhythmias who were treated with an antiarrhyth-
mic drug (AAD) or implantable cardioverter-defibrillator (ICD).
BACKGROUND The Antiarrhythmics Versus Implantable Defibrillators (AVID) study demonstrated im-
proved survival in patients with ventricular fibrillation or ventricular tachycardia with a left
ventricular ejection fraction (LVEF) #0.40 or hemodynamic compromise.
METHODS Survival differences between AAD-treated and ICD-treated patients entered into the AVID
study (patients presenting with sustained ventricular arrhythmia associated with an LVEF
#0.40 or hemodynamic compromise) were compared at different levels of ejection fraction.
RESULTS In patients with an LVEF $0.35, there was no difference in survival between AAD-treated
and ICD-treated patients. A test for interaction was not significant, but had low power to
detect an interaction. For patients with an LVEF 0.20 to 0.34, there was a significantly
improved survival with ICD as compared with AAD therapy. In the smaller subgroup with
an LVEF ,0.20, the same magnitude of survival difference was seen as that in the 0.20 to
0.34 LVEF subgroup, but the difference did not reach statistical significance.
CONCLUSIONS These data suggest that patients with relatively well-preserved LVEF ($0.35) may not have
better survival when treated with the ICD as compared with AADs. At a lower LVEF, the
ICD appears to offer improved survival as compared with AADs. Prospective studies with
larger patient numbers are needed to assess the effect of relatively well-preserved ejection
fraction ($0.35) on the relative treatment effect of AADs and the ICDs. (J Am Coll Cardiol
1999;34:1090–5) © 1999 by the American College of Cardiology
Patients surviving life-threatening ventricular tachyarrhyth-
mias are at high risk for a fatal recurrent arrhythmia (1,2).
The Antiarrhythmics Versus Implantable Defibrillators
(AVID) study showed that treatment with an implantable
cardioverter-defibrillator (ICD) is more effective in prevent-
ing death in these patients than empiric antiarrhythmic drug
(AAD) therapy (almost all drug-treated patients in AVID
received amiodarone) (3).
See page 1096
Although the results of AVID apply, in principle, to the
entire trial population, there was a substantial variation in
the left ventricular function of these patients. Specifically,
the difference in treatment effect might be less in patients
with a lower ejection fraction. Although mortality generally
increases with increasing New York Heart Association
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(NYHA) functional class, the proportion of deaths that are
sudden declines from 50% to 80% in functional class II to
5% to 30% in functional class IV (4). In other words, the
“sicker” patients are more likely to die of progressive heart
failure rather than suddenly, presumably due to a fatal
arrhythmia. Because the competing risks for mechanism of
death have different likelihoods of occurring depending on
heart failure severity, we reasoned that the relative effective-
ness of the ICD and AAD might be different in patients
with different left ventricular ejection fractions (LVEFs).
Observational studies have suggested that the efficacy of
amiodarone may vary with the extent of left ventricular
dysfunction (5).
The purposes of this study were 1) to examine the effect
of LVEF at randomization on the survival difference be-
tween patients treated with AAD and ICD therapy; and 2)
to present survival data on patients with a spectrum of left
ventricular function after a sustained ventricular tachyar-
rhythmia who are treated with an AAD (essentially amio-
darone) or the ICD for use in planning future intervention
trials.
METHODS
The AVID study was a multicenter, randomized compari-
son of two treatment strategies for patients who had
survived a life-threatening sustained ventricular tachyar-
rhythmia. The study design and results have been presented
elsewhere (3,6). Briefly, patients resuscitated from ventric-
ular fibrillation (VF), sustained ventricular tachycardia (VT)
with syncope or sustained VT with an LVEF #0.40 and
symptoms suggesting severe hemodynamic compromise due
to the arrhythmia (near-syncope, congestive heart failure
and angina) were randomized to receive an ICD or phar-
macologic therapy. The primary end point was mortality
from any cause.
Statistical analysis. The relative effects of ICD and AAD
therapy to prevent death were evaluated for prospectively
defined subgroups of LVEF $0.35 and ,0.35. The test for
an interaction between treatments in these two subgroups
was not significant, although the point estimate of the
hazard ratio in the higher LVEF group was closer to 1 as
compared with the study-wide hazard ratio of 0.62 (3). The
confidence interval for the point estimate in the higher
ejection fraction group does not permit distinction between
chance fluctuation and low power. We speculated that a
LVEF of 0.35 might not be low enough to select a group
with substantial competing causes of death. The patients
were subgrouped post hoc according to whether the LVEF
was ,0.20, 0.20 to 0.34 or .0.34. Within each subgroup,
survival functions were estimated by the methods of
Kaplan-Meier and compared between drug and device by
the log-rank statistic. A simple proportional hazards regres-
sion model (Cox) involving only the left ventricular sub-
group category and treatment arm was used to test for an
interaction between the LVEF level and treatment. The
LVEF subgrouping was treated as a categoric variable rather
than an ordered variable because the published data sug-
gested that the relative benefit of the ICD would be
diminished in the very low ejection fraction group and the
previously described analysis suggested that the effect was
diminished in the high LVEF subgroup. To improve the
efficiency of the test, comparisons were made within the
ejection fraction strata, adjusting for baseline factors known
to be related to survival. These include age, index arrhyth-
mia, gender, NYHA functional class, history of diabetes,
history of myocardial infarction, coronary artery disease and
therapy at discharge with beta-adrenergic blocking agents or
an angiotensin-converting enzyme (ACE) inhibitor.
RESULTS
Baseline characteristics of study group. Baseline charac-
teristics of the study group are shown in Table 1, grouped
according to LVEF (Group 1 ,0.20; Group 2 0.20 to 0.34;
Group 3 .0.34). Significant relations (p # 0.05) were
found between ejection fraction and histories of myocardial
infarction and congestive heart failure, and ejection fraction
at hospital discharge (Table 2) when coronary artery bypass
graft surgery, amiodarone, beta-blockers, calcium blockers,
digitalis or ACE inhibitors had been used. There was no
relation between LVEF and a history of VT or VF.
Adverse cardiovascular outcomes. Most patients assigned
to AAD treatment received amiodarone (97%). Crossover
rates were modest (18% at two years) in both arms of group
3 and increased to 24% and 31% for the middle and lowest
LVEF groups, respectively (Table 3). Overall, survival at
one and two years was 89.3 6 2.9% and 81.6 6 4.1%,
respectively, in the ICD-treated patients, and 82.3 6 3.5%
and 74.7 6 4.4% in AAD-treated patients. For patients
with an LVEF ,0.20, the survival rate was 82.4 6 10.4%
and 71.6 6 14.6% at one and two years in the ICD-treated
patients, respectively, and 73.0 6 10.0% and 63.8 6 11.6%
in the AAD-treated patients (Fig. 1). In patients with an
LVEF between 0.20 and 0.34, the overall survival rate was
89.2 6 4.1% and 82.5 6 5.7% at one and two years,
respectively, in the ICD-treated patients and 79.8 6 5.5%
Abbreviations and Acronyms
AAD 5 antiarrhythmic drug
ACE 5 angiotensin converting enzyme
AVID 5 Antiarrhythmics Versus Implantable
Defibrillators study
ICD 5 implantable cardioverter-defibrillator
LVEF 5 left ventricular ejection fraction
NYHA 5 New York Heart Association
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
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and 71.8 6 6.7% in the AAD-treated patients. In patients
with an LVEF .0.34, there was no difference in survival
between AAD-treated and ICD-treated patients. The for-
mal test for an interaction did not reach statistical signifi-
cance, but the test had low power. For patients with an
LVEF between 0.20 and 0.34, there was a significantly
improved survival with ICD as compared with AAD
therapy (p , 0.05). In the smaller subgroup with an LVEF
,0.20, the same magnitude of survival difference was seen
as in the 0.20 to 0.34 LVEF group, but the difference did
not reach statistical significance.
The survival differences in each of the left ventricular
function strata were relatively unchanged when adjusted for
the covariates listed already, including the use of beta-
blockers. The relative hazard estimates (and associated p
values) for AAD as compared with ICD therapy obtained
from the proportional hazard model were 1.70 (p 5 0.13),
1.46 (p 5 0.08) and 1.21 (p 5 0.52) for the lower,
intermediate and higher LVEF groups, respectively, after
adjustment for other clinical characteristics, including his-
tory of atrial fibrillation, which, in the LVEF ,0.20 group,
was greater in the AAD-treated patients.























Age (yr) 65.4 64.8 65.0 64.7 65.7 65.2 64.7 65.1 64.9
Male (%) 81.5 86.0 84.3 79.3 79.3 79.3 76.5 79.2 77.8
White (%) 85.2 86.0 85.7 86.6 84.1 85.4 88.2 87.0 87.6
CAD (%) 74.1 80.2 77.9 85.8 84.1 85.0 78.4 78.6 78.5
History of (%)
VT 14.8 19.8 17.9 15.0 13.7 14.4 11.8 14.1 12.9
VF 5.6 4.7 5.0 4.1 4.4 4.2 4.4 5.2 4.8
MI 68.5 65.1 66.4 72.0 71.8 71.9 60.8 63.0 61.9
DM 20.4 16.3 17.9 30.5 29.1 29.8 18.6 22.4 20.5
CHF 79.6 68.6 72.9 48.8 52.4 50.5 33.8 32.8 33.3
CABG 20.4 31.4 27.1 32.5 32.2 32.3 28.4 27.6 28.0
AF 7.4 27.9 20.0 21.5 24.2 22.8 23.5 27.6 25.5
AAD 5 antiarrhythmic drug; AF 5 atrial fibrillation; CABG 5 coronary artery bypass graft surgery; CAD 5 coronary artery disease; CHF 5 congestive heart failure; DM 5
diabetes mellitus; ICD 5 implantable cardioverter-defibrillator; MI 5 myocardial infarction; VF 5 ventricular fibrillation; VT 5 ventricular tachycardia.




Group 1 Group 2 Group 3
ICD AAD Total ICD AAD Total ICD AAD Total
Discharge therapy (%)
ACEI 81.5 79.1 80.0 80.4 74.6 77.6 50.2 57.8 53.9
Other vasodilator 7.4 11.6 10.0 7.3 7.1 7.2 4.9 4.7 4.8
Beta-blocker 24.1 5.8 12.9 34.7 16.9 26.2 54.2 19.9 37.6
Calcium blocker 11.1 2.3 5.7 15.5 10.2 13.0 22.2 20.3 21.3
Digoxin 64.8 64.0 64.3 56.7 48.9 53.0 29.1 22.9 26.1
CABG 9.3 4.7 6.4 11.4 13.2 12.3 3.4 5.7 4.5
Amiodarone 3.7 98.8 62.1 3.3 94.2 46.8 0.5 95.3 46.6
Sotalol 0.0 0.0 0.0 0.4 3.1 1.7 1.5 3.1 2.3
ICD 94.4 0.0 36.4 98.0 1.3 51.6 96.6 2.6 51.0
ACEI 5 angiotensin-converting enzyme inhibitor; other abbreviations as in Table 1.
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DISCUSSION
In the AVID trial, treatment with an ICD was found to
result in improved survival as compared with treatment with
an AAD. The present study suggests that the difference may
be modulated by the degree of left ventricular dysfunction.
Patients with moderate to severe left ventricular dysfunction
(group 2) appeared to have improved survival with ICD as
compared with AAD therapy. The magnitude of the dif-
ference persisted in group 1 (patients with profoundly
depressed ejection fraction), although statistical significance
was not reached, probably because of the small number of
patients (n 5 140). For patients with relatively well-
preserved left ventricular function (LVEF $0.35), the data
suggest that survival of ICD-treated patients is no better
than that of AAD-treated patients.
The reason for the absence of improved survival in
ICD-treated as compared with AAD-treated patients with
higher ejection fractions and the presence of improved
survival in the ICD-treated patients with low and very low
ejection fractions cannot be explained with certainty. Given
the wide confidence intervals, the simple play of chance
cannot be excluded. However, a weak protective effect of
amiodarone in preventing arrhythmic death has been dem-
onstrated in patients who have had a myocardial infarction
(7,8), and observational studies suggest that the benefit of
AAD therapy may be greater in patients with a higher
LVEF (5), whereas the ICD is highly effective in converting
malignant ventricular arrhythmias regardless of ejection
fraction. It is possible that in ventricles with better left
ventricular function, amiodarone is relatively more effective
in preventing malignant ventricular arrhythmias than in the
“sicker” ventricles of patients with moderately and severely
reduced ejection fraction. If this were the case, amiodarone
in the group 3 patients may have reduced the mortality and
done so with enough effectiveness to reduce the mortality
differences between the treatment modalities. That this
may, indeed, be the case is supported by evidence from
several studies. Goldstein et al. (9) studied post–myocardial
infarction patients followed in the Cardiac Arrhythmia
Suppression Trial (CAST). These investigators showed that




Group 1 Group 2 Group 3
ICD AAD Total ICD AAD Total ICD AAD Total
Crossover rate
At 1 year 27.5 9.0 16.4 20.9 12.0 16.7 11.5 13.8 12.5
At 2 year 38.7 25.2 30.9 30.3 16.6 24.0 18.5 18.4 18.4
*In most instances, crossover consisted of addition (rather than substitution) of the other therapy. Abbreviations as in Table 1.
Figure 1. Survival of patients in different ranges of ejection fraction treated with an AAD or ICD. Cum 5 cumulative; N 5 number of
patients; Rel-Risk 5 relative risk.
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the ease of suppressing ventricular ectopy correlated with
improved survival. Spielman et al. (10) studied predictors of
success in suppressing recurrent sustained VT in 84 patients
with this arrhythmia. They found that higher ejection
fraction and the absence of aneurysm and hypokinesia
correlated with suppressibility. Meissner et al. (11) studied
the relation between ejection fraction and antiarrhythmic
drug efficacy in suppressing inducibility at electrophysiologic
study of VT in 201 patients with a history of VT or VF. In
this study, ejection fraction was the only factor that corre-
lated significantly with drug success or failure in suppressing
inducibility. High crossover rates can obscure differences.
However, crossover rates were low in group 3, where no
difference was observed, and higher in groups 1 and 2,
where differences were observed. Also, patients with a better
LVEF may die of causes not correctable with an ICD.
Survival data. Patients resuscitated from a life-threatening
ventricular tachyarrhythmia have a particularly poor long-
term prognosis (12). Also, LVEF is a strong prognostic
indicator for survival (12). Apart from beta-blockers, aspirin
and perhaps ACE inhibitors, only two modalities—
amiodarone and the ICD—have been demonstrated to have
efficacy in the prevention of arrhythmic death. The data
presented here provide information on the survival of
patients presenting with ventricular tachyarrhythmias and
varying degrees of left ventricular dysfunction who are
treated with either an AAD or ICD. The data presented
involve patients from the current era who were treated with
conventional ancillary therapy. The two-year survival rate
for these contemporary ICD recipients was 83% in group 3,
83% in group 2 and 72% in group 1. For contemporary
AAD-treated patients, the two-year survival was 83% in
group 3, 72% in group 2 and 64% in group 1. These data
should prove useful in designing future clinical trials, par-
ticularly in sample size calculations.
Comparison to previous studies. The survival rate of
patients in AVID is comparable to that observed in a
number of other studies that have been published during the
last five years. Fogoros et al. (13) reported a two-year
survival rate of 76% in ICD-treated patients who had
drug-refractory VT or VF and an LVEF ,0.30. Powell et
al. (14) reported a two-year survival rate of ;86% in
post–cardiac arrest ICD-treated patients. Wever et al. (15)
reported 29 patients with a mean LVEF of 0.30 who had
ICD placement after cardiac arrest. The survival rate at a
median follow up of two years was 86%. In the Cardiac
Arrest Study Hamburg (16), post–cardiac arrest patients
randomized to receive amiodarone who had an LVEF
,0.25 had a 60% two-year survival rate, which is similar to
the findings in AVID. In the Cardiac Arrest in Seattle:
Conventional vs Amiodarone Drug Evaluation (CAS-
CADE) study (17), post–cardiac arrest patients randomized
to receive amiodarone with an LVEF ,0.30 had a two-year
survival rate of 60%, which is comparable to the AVID
results for patients with an LVEF ,0.20. For the CAS-
CADE patients, the survival rate of patients with an LVEF
0.25 to 0.34 was 74%, almost precisely the same as the 72%
survival rate reported for AVID patients with similar left
ventricular function (17).
Comparison with other recent studies suggests that the
mortality rates for AVID patients undergoing treatment in
the current era are similar to those for patients in studies
reported during the last five years. These data also empha-
size the importance of considering ejection fraction in
planning clinical trials of patients similar to those in the
AVID population.
Study limitations. This study was a retrospective subgroup
analysis. Furthermore, the relatively small numbers of pa-
tients at risk after two years limit the value of comparison
beyond two years. Also, the test of an interaction between
ejection fraction and mortality did not reach statistical
significance. However, the power of the test to detect an
interaction was limited.
Clinical implications. The overall AVID trial demon-
strated improved survival of ICD-treated as compared with
AAD-treated patients after resuscitation from a sustained
ventricular tachyarrhythmia. These subgroup data suggest
that the benefit of ICD over AAD occurred mainly in
patients with a moderately severe reduction in left ventric-
ular function (LVEF 0.20 to 0.35) who survive a sustained,
life-threatening ventricular tachyarrhythmia. This recom-
mendation should also be made for patients with profound
left ventricular dysfunction (LVEF ,0.20). The results raise
the question of whether AADs may result in similar survival
outcome as with ICD treatment in patients with relatively
well-preserved left ventricular function. Only a suitably
powered, randomized trial can answer this question.
Conclusions. These data suggest that patients with rela-
tively well-preserved LVEF ($0.35) may not have better
survival when treated with an ICD as compared with an
AAD. At lower LVEFs, the ICD appears to offer improved
survival as compared with AAD. Prospective studies with
larger patient numbers are needed to assess the effect of
relatively well-preserved ejection fraction ($0.35) on the
relative treatment effect of AAD and ICD.
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